Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000606884 | SCV000713315 | likely benign | not specified | 2017-06-28 | criteria provided, single submitter | clinical testing | p.Glu481Lys in exon 10B of P2RX2: This variant is not expected to have clinical significance due to a lack of conservation across species, including mammals. Of note, at least 3 mammals have a lysine (Lys) at this position. In addition, com putational prediction tools do not suggest a high likelihood of impact to the pr otein. It has also been identified in 0.1% (20/34408) of Latino chromosomes by t he Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs199955493). |
Gene |
RCV000992498 | SCV000722378 | likely benign | not provided | 2020-09-24 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000992498 | SCV001144861 | benign | not provided | 2019-07-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000992498 | SCV002189119 | likely benign | not provided | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000606884 | SCV003614166 | uncertain significance | not specified | 2021-07-09 | criteria provided, single submitter | clinical testing | The c.1441G>A (p.E481K) alteration is located in exon 10 (coding exon 10) of the P2RX2 gene. This alteration results from a G to A substitution at nucleotide position 1441, causing the glutamic acid (E) at amino acid position 481 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |